Notes from the Field: Rollout of Nirsevimab to Protect Infants and Young Children During the Respiratory Syncytial Virus Season — New York City, 2023–2024
by from Morbidity and Mortality Weekly Report (MMWR) on (#6SQN5)
This report describes the percentage of New York City infants born during the recommended nirsevimab adminstration period who received nirsevimab.